Dette gleder jeg meg til. FĂ„ ut data og vurderinger fra hus og biotekere! Allerede til uka kan det bli gode diskusjoner etter disse konferanser hvor resultater blir presentert.
Oslo, Norway, February 23, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that that the international multicenter Phase III clinical study of CeviraÂź (APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), has been selected for late breaking oral presentation at the 2024 SGO Annual Meeting on Womenâs Cancer of the Society of Gynecologic Oncology, to be held March 16-18 in San Diego, CA, USA:
- Oral presentation: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase â
ą global study
Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1, on March 17, 2024)
Oslo, Norway, February 22, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of CeviraÂź(APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN), held March 13-16 in Stockholm, Sweden:
- Oral presentation (Abstract No.6802) Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase â
ą global study (YHGT-CEV-R1/APRICITY)
Kan nesten ikke vente! Biotek er spennende, for Ă„ si det forsiktig. Lykkes det er det sĂ„ gĂžy! Mer tilfredsstillende enn Ă„ lykkes innen helse kan jeg ikke tenke meg. Dobbeleffekt. Pasienter og stakeholders fĂ„r en bedre hverdagđ. Er Cevira over mĂ„lstreken en innertier?